Shared from twixb · endpts.com

Pfizer CFO to depart; GSK wins approval for UTI drug

endpts.com·Jun 18, 2026

Pfizer's CFO is set to depart the company, while GSK has received approval for a new drug to treat urinary tract infections.

The most actionable insight from the content is that GSK has received approval for a UTI drug, which could be a significant development in the pharmaceutical sector and may present investment opportunities or partnerships in the realm of precision medicine and biotech. This approval indicates a regulatory success that can impact market dynamics and influence strategic decisions within the healthtech and biotech industry.

Want more content like this?

twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.

Create Your Own →Explore Newsfeeds

More from Healthtech & Biotech News

Recent stories curated alongside this one.

statnews.com
STAT+: Up and down the ladder: The latest comings and goings
The article highlights recent personnel changes in the pharmaceutical industry, including new hires, promotions, and transfers, with a focus on Jae Kim's appointment as chief medical officer at Protego Biopharma. It encourages readers to share updates about job movements within the sector.
endpts.com
Treasury weighs screening investments in China biotech
The U.S. Treasury Department is considering implementing restrictions on American investments in China's biotechnology sector, according to sources familiar with the discussions.
statnews.com
STAT+: Do wearables actually help people with cardiovascular disease?
The article explores the effectiveness of wearable technology in managing cardiovascular diseases, highlighting research findings on their potential benefits for patients. It aims to provide insights into how these devices might aid in monitoring and improving heart health.
statnews.com
STAT+: Cambrian’s experimental longevity drug mimics exercise
Cambrian's experimental longevity drug has shown potential in mimicking the effects of exercise, contributing to the latest advancements in biotechnology. The article also highlights other significant biotech news, including developments from Enanta and Patrick Soon-Shiong's claims regarding pancreatic cancer treatments.
endpts.com
RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea
RA Capital, Forbion, and Sanofi Ventures are reportedly investing in a new eye drug developed by a biotech company from Korea, continuing the trend of major venture investors collaborating to support innovative medical treatments.

Browse all Healthtech & Biotech News →

Pfizer CFO to depart; GSK wins approval for UTI drug

Want more content like this?

More from Healthtech & Biotech News

STAT+: Up and down the ladder: The latest comings and goings

Treasury weighs screening investments in China biotech

STAT+: Do wearables actually help people with cardiovascular disease?

STAT+: Cambrian’s experimental longevity drug mimics exercise

RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea